Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk

18.01.2005


In two articles, published in Circulation, researchers from the University of Pennsylvania School of Medicine provide further evidence for the role of cyclooxygenases (COX) in heart-disease risk. In one, a statistical meta-analysis of two placebo-controlled trials, the COX-2 inhibitor Bextra elevated the combined incidence of heart attack and stroke three-fold in coronary artery bypass graft (CABG) surgery patients. In the second, the investigators found that a fat produced by COX-1 speeds hardening of the arteries in a mouse model of atherosclerosis, which may have implications for low-dose aspirin therapy in heart patients.



Six years ago Garret FitzGerald, MD, Director of the Institute for Translational Medicine and Therapeutics at Penn, raised the possibility that selective COX-2 inhibitors might predispose patients otherwise at risk for an increased incidence of heart attack and stroke. This proposal was based initially on his studies of how celecoxib (Celebrex) and rofeocoxib (Vioxx) worked in human volunteers.

The first unequivocal evidence of this risk emerged with the Merck-sponsored APPROVe study of Vioxx, leading to withdrawal of the drug in September 2004. Evidence implicating a second member of the class, valdecoxib (Bextra) was presented by FitzGerald in a lecture at the American Heart Association (AHA) in November 2004. This work – a collaboration led by Curt Furberg of Wake Forrest University, along with Bruce Psaty of the University of Washington and FitzGerald – appears online January 17 in Circulation and in the January 25th print edition of the journal.


In this first study, the researchers used a conventional statistical approach called meta-analysis to combine the findings of two trials to obtain a stronger estimate of the risk of heart attack plus stroke than is possible from looking at either trial alone. Their analysis suggests that the COX-2 inhibitor Bextra elevated the combined incidence of heart attack and stroke three-fold in the study population of CABG patients.

Two placebo-controlled trials of Bextra and parecoxib (Dynastat) were performed in patients undergoing coronary artery bypass graft surgery. These studies were sponsored by Pfizer, Inc. In both cases, intravenous Dynastat, which is converted to Bextra within minutes in the body, was given before oral dosing with Bextra. The first involved roughly 400 patients and dosing lasted 14 days. Concern was prompted by an apparent cardiovascular signal and the FDA did not grant approval to Dynastat, despite clear evidence of pain relief from the Dynastat/Bextra combination compared to placebo. A second, larger study was performed in which the dose of Bextra was reduced, as was the dosing period to 10 days. The figures from this study are now incorporated in a revised drug label for Bextra available at the FDA website (www.fda.gov).

This result is consistent with the original mechanism proposed by FitzGerald in 1999 that COX-2 inhibitors may be problematic for those at risk for heart disease. COX-2 is the main source of a fat – prostacyclin or PGI2 – which protects the heart from factors that activate the clotting system, harden the arteries, and raise blood pressure. "Although a clinical trial is a crude detection system for uncommon side effects, such as the cardiovascular risk from coxibs, we predicted that a signal would be detected faster and in smaller studies in patients with activated clotting systems," says FitzGerald. "It is well known that this is true of coronary artery bypass graft surgery patients." Studies of sufficient size and duration to detect the expected rates of cardiovascular events in arthritis patients have not been performed with Bextra.

While FitzGerald stresses that the emergence of a cardiovascular signal with a second COX-2 inhibitor rendered the argument for a class effect of the risk "compelling," the early cessation of a placebo-controlled trial of celecoxib (Celebrex) in December 2004 by the National Cancer Institute (because of an excess incidence of heart attack and stroke) appeared to put the matter beyond dispute.

A related paper from the FitzGerald group also appears online in the same issue of Circulation. Karine Egan, PhD, a postdoctoral researcher in the FitzGerald lab, and colleagues at Penn and the Wistar Institute studied mice genetically prone to hardening of the arteries (atherosclerosis) and showed that another fat – thromboxane or TxA2, this time produced by COX-1 – accelerates atherosclerosis. Indeed, they showed a drug that blocks TxA2 slowed this process at its early stages, although it seemed ineffective once atherosclerosis was well established. "This is of particular interest, as low-dose aspirin prevents heart attack and stroke by blocking COX-1 formation of TxA2 in blood cells called platelets," says FitzGerald. "Its effects or those of a TxA2 blocker on hardening of the arteries has never been studied well in humans."

Egan and colleagues failed to detect a benefit from COX-2 inhibition in the atherosclerosis-prone mice, but they reasoned that a potential benefit might be masked by the effect of the drug. Although platelet COX-1 is the major source of TxA2, this fat can also be formed by COX-2 in cells called macrophages that invade the hardening vessel wall. Given what they had seen with the TxA2 blocker, FitzGerald’s group figured that they might need to add the TxA2 blocker to see the anti-inflammatory benefit of the COX-2 inhibitor.

Adding the COX-2 inhibitor not only failed to add to the beneficial effects of the TxA2 blocker, it caused disturbing changes in the makeup of the atherosclerotic plaques. "We were amazed," states Egan. "Addition of the COX-2 inhibitor caused changes that, if they occurred in humans, would result in a loss of stability of the plaque, making it more likely to rupture and activate clotting, causing heart attack or stroke."

"We must always be cautious projecting the results of studies in mice to clinical outcomes in humans," says FitzGerald. "While low-dose aspirin works by switching off TxA2, a TxA2 blocker might act in subtle, but importantly different ways. However, in so far as it mimics the effects of low-dose aspirin, these results would have disturbing implications for patients at high cardiovascular risk treated with aspirin and a coxib."

FitzGerald adds: "The clear emergence of a cardiovascular hazard from COX-2 inhibitors in patients, the weak rationale for a study of their protective properties in the first instance, and now this evidence from mice would indicate to me that a trial in high-risk patients, such as that proposed for Celebrex is, at best, ill advised."

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>